argenx NV ADR (ARGX) revenue breakdown

Healthcare · Biotechnology · Market cap $50.6B

By region, United States is the largest at 84% of fiscal 2023 revenue, growing -69% a year over 2 years.

Revenue by region

Fiscal years, as argenx NV ADR reports them in its 10-K filings; fiscal 2023 total $36M.

Regions20162017201820192020202120222023Share
United States—————$317M—$30M 84%
China—————$178M$4M$6M 16%
Denmark$3M$6M$1M$488,000$342,000$1M$5M— —
Other—————$123,000$424,000— —
United States——$19M$76M$41M——— —
Luxembourg$7M$27M—————— —
Switzerland$3M$2M—————— —
BELGIUM———$2M———— —
Other——$1M————— —
Netherlands$548,000$628,000—————— —
Germany$311,000——————— —
United States$47,000——————— —
United States—$1,000—————— —
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARGX.
Open ARGX in Investingly

Questions

Where does argenx NV ADR make its money?

In fiscal 2023, by region: United States $30M, China $6M.

From argenx NV ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.